Abstract
This article provides a summary of the available lipid-lowering therapies in the UK and how they fit into national guidelines. In addition, comparison is made between the current National Institute for Health and Care Excellence lipid modification guidelines and international guidance such as those published by the European Society of Cardiology/European Atherosclerosis Society and American Heart Association/American College of Cardiology.
Subject
Cardiology and Cardiovascular Medicine
Reference29 articles.
1. Public Health England . Health matters: preventing cardiovascular disease: PHE publication gateway reference: GW-154, 2019.
2. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
3. NICE . Clinical guideline [CG181]: Cardiovascular disease: risk assessment and reduction, including lipid modification, 2016.
4. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
5. NICE . Technology appraisal guidance [TA733]: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia, 2021.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献